Search clinical trials for: Lymphoproliferative Disorder

Total 148475 results

Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Germany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Australia, Denmark, Sweden, Brazil, China, Spain, Czechia, Turkey, Poland, Netherlands, Argentina, Canada, United Kingdom, Greece, India
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
M.D. Anderson Cancer Center
Pfizer

Not yet recruiting

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Multiple Myeloma | Post-transplant MRD-guided Maintenance Therapy | Pre-transplant Purging

United States
Beijing Immunochina Medical Science & Technology...
Peking University People's Hospital

Not yet recruiting

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

Leukemia, B-cell
Oncotherapeutics
Incyte Corporation

Not yet recruiting

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Multiple Myeloma
Shanghai Simnova Biotechnology Co.,Ltd.
Wuhan Union Hospital, China

Recruiting

F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

China
IRCCS Policlinico S. Matteo

Recruiting

A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA) (EUREKA)

AL Amyloidosis

Germany, Italy, Spain, Switzerland, Netherlands
University of Chicago

Not yet recruiting

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Lymphoblastic Lymphoma | Acute Leukemia | Lymphoblastic Leukemia

United States
Shenzhen TargetRx, Inc.
Institute of Hematology & Blood Diseases Hospital, China

Recruiting

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Non Hodgkin Lymphoma | Hematologic Malignancy | Acute Lymphoblastic Leukemia, Adult

China
AstraZeneca
Yghea

Recruiting

Acalabrutinib Real World Italian obSErvational Study -ARISE (ARISE)

Chronic Lymphocytic Leukemia

Italy
Molecure S.A.

Recruiting

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

United States, United Kingdom
Peking University First Hospital

Recruiting

A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM

Multiple Myeloma | Renal Injury

China
Shanghai Zhongshan Hospital

Recruiting

The Pathogenesis and Prognostic Factors of Lymphoma

Lymphoma | Hodgkin Lymphoma | Non-hodgkin Lymphoma

China
Elvira Umyarova
Sanofi

Recruiting

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Poitiers University Hospital

Recruiting

Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Waldenstrom's Macroglobulinaemia Refractory

France
Xuzhou Medical University

Recruiting

Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

Multiple Myeloma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
Jin Lu, MD

Recruiting

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

AL Amyloidosis | Amyloidosis; Systemic

China
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Recruiting

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Mantle Cell Lymphoma | MCL

United States
Zhongshan Ophthalmic Center, Sun Yat-sen University

Recruiting

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

Primary Ocular Adnexal MALT Lymphoma

China
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico, Australia, Israel, Korea, Republic of, Romania, Serbia, Spain, Taiwan
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

China
National Research Center for Hematology, Russia

Recruiting

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Primary Mediastinal Lymphoma

Russian Federation
University Medical Center Groningen
Takeda

Not yet recruiting

CD30 Imaging in Diffuse Large B-cell Lymphoma

Diffuse Large B-cell-lymphoma
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM)

Multiple Myeloma
Midwest Heart & Vascular Specialists

Recruiting

Amyloidosis Incidence in High-Risk Cardiac Device Patients

AL Amyloidosis | Amyloid | Cardiac Amyloidosis | Amyloidosis Cardiac | Systemic Amyloidosis | ATTR Amyloidosis Wild Type | Infiltrative Cardiomyopathy, Amyloid

United States
Washington University School of Medicine
Paula C. & Rodger O. Riney Blood Cancer Research

Not yet recruiting

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Multiple Myeloma

United States
Jae Wook Lee

Not yet recruiting

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia (KPHOG_2023-02)

Pediatric Acute Lymphoblastic Leukemia
OriCell Therapeutics Co., Ltd.

Recruiting

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

Relapsed and/or Refractory Multiple Myeloma

China
Stichting European Myeloma Network
Pfizer

Recruiting

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM)

Smoldering Multiple Myeloma

Netherlands, France, Italy, Greece, Finland, Norway
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR); Myeloma Canada

Recruiting

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Canada
Children's Hospital Los Angeles

Not yet recruiting

Reduce Sedentary Time (ReSeT) in Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia (ALL)
Chongqing Precision Biotech Co., Ltd
Peking University Cancer Hospital & Institute

Recruiting

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma | Non Hodgkin Lymphoma

China
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

China
National Cancer Institute (NCI)

Recruiting

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Multiple Myeloma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type

United States
Yan Zhang, MD
Peking University First Hospital; Chinese PLA General Hospital; Peking University...

Recruiting

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Diffuse Large B Cell Lymphoma

China
PETHEMA Foundation

Not yet recruiting

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL (LALPh2022)

Lymphoblastic Leukemia | Adult ALL | Philadelphia-Positive ALL
Navy General Hospital, Beijing
Chinese PLA General Hospital

Recruiting

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma

Relapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell Lymphoma

China
Providence Health & Services

Recruiting

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Primary Central Nervous System Lymphoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United States, Spain, United Kingdom
Multiple Myeloma Research Consortium

Not yet recruiting

Horizon Adaptive Platform Trial Evaluating Therapies in RRMM

Refractory Multiple Myeloma | Relapse Multiple Myeloma
University of Alberta
Alberta Health services

Recruiting

Pediatric Early Rehabilitation in Acute Lymphoblastic Leukemia (PEACE)

Neoplasms | Telemedicine | Pediatric Cancer | Physical Therapy

Canada
AstraZeneca

Recruiting

REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania (REACH)

Chronic Lymphocytic Leukemia

Romania
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Hodgkin Lymphoma

China
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States

Search clinical trials for: Lymphoproliferative Disorder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations